NMN for Sarcopenia: What the Evidence Actually Shows

By T Dinaiz · BSc Molecular Biology, MSc Biotechnology

Last reviewed 2026-04-28. NMN's evidence base, and Malaysian NPRA/JAKIM/price details, can change - confirm current status with primary sources and a registered doctor before acting.

What sarcopenia actually is

Sarcopenia is the progressive, age-related loss of muscle mass, strength and physical function. It is not the same as being thin, and not the same as the wasting that follows acute illness. The condition develops slowly, often unnoticed, until a moment of clinical visibility - a fall in the kitchen, difficulty rising from the toilet, slowed walking on a tiled hospital corridor, a hand that can no longer twist open a kicap bottle.

The clinical definition has been refined over the past decade. The European Working Group on Sarcopenia in Older People (EWGSOP) revised its consensus in 2019, and the Asian Working Group for Sarcopenia (AWGS) issued its own 2019 update tailored to Asian body composition.

Both frameworks agree on the three pillars: low muscle quantity, low muscle strength, and low physical performance. The Asian thresholds are lower than the European ones because Asian adults carry less absolute muscle mass on average, even at the same BMI.

A practical AWGS 2019 cut-off set looks like this: grip strength below 28 kg in men or below 18 kg in women indicates low strength; gait speed below 1.0 m/s indicates low physical performance; and appendicular skeletal muscle mass index below 7.0 kg/m squared in men or 5.4 kg/m squared in women (by DXA) indicates low quantity.

Why this matters for an aging Malaysia

Malaysia is aging quickly. The Department of Statistics projects that adults aged 65 and above will exceed 10 percent of the population by 2030 and continue rising.

The implication for the healthcare system is significant: more falls, more hip fractures, more rehabilitation needs, more pressure on geriatric beds. The implication for individual families is felt earlier - a parent who can no longer climb the stairs at home, a grandparent whose grip is too weak to safely hold a child.

Grip strength is a particularly useful marker because it predicts so much. Several large cohort studies have found grip strength to be a stronger predictor of all-cause mortality than systolic blood pressure in adults over 65. A weak hand is a flag for systemic decline, not just a hand problem.

For Malaysian patients, the conversation about sarcopenia tends to arrive too late. Many older adults present to a GP, IMU clinic or Klinik Kesihatan with falls, weight loss or weakness, and the concept of sarcopenia as a named condition is unfamiliar.

Building that vocabulary into routine geriatric care matters because the interventions - resistance training, protein adequacy, vitamin D, addressing polypharmacy - work, and they work better when started earlier in the trajectory.

Igarashi 2022 in detail

The Igarashi et al. (2022) trial, published in npj Aging, is the most relevant human NMN trial for sarcopenia and the one Malaysian clinicians and patients should understand in detail.

Population: 42 healthy Japanese men aged 65 years or older. The participants were community-dwelling, not frail, not on resistance-training programmes, and without major chronic disease. Baseline handgrip strength was within the normal-to-low range for the AWGS framework.

Intervention: Oral NMN 250mg once daily, with the dosing time randomised to either morning or afternoon to test circadian effects. Comparison was placebo. Duration was 12 weeks.

Primary measures: Grip strength (right and left hand), 5-time chair-stand test, walking speed (4-metre gait speed), and a battery of physical performance and biomarker outcomes.

Findings: The morning-dose NMN arm showed statistically significant improvements in walking speed and a positive trend in grip strength. The afternoon-dose arm showed less consistent benefit, suggesting that timing matters and morning dosing aligns better with the circadian rhythm of NAD+ and SIRT1 activity. No serious adverse events were reported.

Effect size honesty: The improvements were measurable but modest. This is not a trial that turned frail elders into vigorous athletes. It is a trial that showed a small biological signal in older men taking 250mg NMN in the morning over three months, without resistance training as a co-intervention.

Okabe et al. (2022) is useful here for a narrower reason: it supports short-term human safety and blood NAD+ bioavailability after oral NMN, not sarcopenia treatment. The grip-strength and walking-speed signal comes from Igarashi; Okabe helps frame tolerability.

The mechanism: NAD+ to SIRT1 to PGC-1alpha

The biological rationale for NMN in sarcopenia rests on a well-described axis. NAD+ levels decline with age in skeletal muscle, as Gomes et al. (2013) and others have demonstrated, leading to reduced sirtuin activity.

SIRT1 activates PGC-1alpha, the master regulator of mitochondrial biogenesis. SIRT1 also modulates the muscle protein synthesis machinery via downstream effects on AMPK and mTOR-related signalling. Lower NAD+ in aging muscle therefore translates to fewer functional mitochondria, reduced fatty-acid oxidation, blunted protein synthesis, and the accumulation of damaged mitochondrial pools.

The review literature on NAD+-boosting molecules frames this as a translational hypothesis rather than a settled clinical pathway. Igarashi 2022 is the human test that matters most for this page: a small physical-performance signal that fits the mechanism, but does not replace training or protein adequacy.

The mechanism does not, however, predict large effects. NAD+ supplementation supports the cellular machinery; it does not build new muscle in the absence of mechanical loading. This is the crucial point that marketing material around NMN often blurs.

Why resistance training comes first

Skeletal muscle is built and preserved by mechanical loading. The largest and most consistent body of evidence for sarcopenia management points to progressive resistance training - weights, resistance bands, body weight done with intent - performed two to three times per week, with adequate protein intake and recovery.

A meta-analytic perspective is sobering: structured resistance training in adults over 65 typically produces gains of 10-30 percent in lower-body strength, measurable improvements in gait speed, reduced falls, and improved chair-stand performance over 12-16 weeks. No supplement, NMN included, comes close to this effect size in trials of similar duration.

For Malaysian context, the practical question is access. Public gyms in Malaysian cities increasingly offer senior-friendly resistance equipment. Klinik Kesihatan physiotherapy departments can prescribe a basic home programme.

PERKESO’s RTW initiatives and the Ministry of Health’s wellness programmes have started to incorporate strength components for older adults. Private gyms and personal trainers in Klang Valley, Penang, JB and Kota Kinabalu offer senior-specific packages.

Even at home, a programme using a single set of dumbbells, resistance bands, and body weight (squats to a chair, modified push-ups against a wall, single-leg stands holding a counter, calf raises on a step) can produce meaningful results. The barrier is rarely equipment; it is consistency and someone to teach safe form initially.

NMN sits as an optional layer on top of this foundation. Without the foundation, NMN is an expensive habit with limited yield.

Protein adequacy: the prerequisite no one talks about

The recommended dietary allowance for protein in older adults has been revised upward in recent years, to roughly 1.2-1.6 grams per kilogram of body weight per day for those over 65, with additional considerations for acute illness or injury. For a 65kg Malaysian adult, that means roughly 78-104g of protein daily, distributed across meals at 25-30g per meal to support the muscle protein synthesis stimulus.

In Malaysian dietary terms, that target is achievable with: one egg or a small piece of fish at breakfast (12-15g protein), a serving of grilled chicken or fish at lunch with dhal or tofu (30-35g), a similar dinner combining chicken or fish with tahu or tempeh (30-35g), and a glass of milk, soya milk or a small handful of nuts as a snack (5-8g).

Many older Malaysians eat well below this target, particularly those on softer textures or limited budgets, and protein supplementation (whey or plant-based) is sometimes the most cost-effective intervention available.

Creatine monohydrate at 3-5g daily is the supplement with the strongest evidence base for sarcopenia management, with multiple randomised trials showing improvements in lean mass and strength when paired with resistance training. Creatine is well-tolerated, inexpensive, and widely available. If a Malaysian patient is choosing between NMN and creatine on a limited budget, creatine wins on evidence.

A 12-week discussion checklist for an older Malaysian adult

The following is a 12-week discussion checklist combining the gold-standard interventions with the questions an older adult might bring to a GP, geriatrician, pharmacist, or physiotherapist.

Resistance training (foundation): Two sessions per week, 30-45 minutes each, focused on the legs (squats, sit-to-stand, step-ups), back (rows, pull-aparts), chest (modified push-ups), and core (bird-dog, dead-bug). Start with body weight or light weights, progress slowly across the 12 weeks.

Daily walking: 30 minutes most days, ideally outdoors when possible to add light vitamin-D exposure.

Protein at every meal: 25-30g target per meal, distributed across breakfast, lunch and dinner.

Creatine monohydrate: 3-5g daily, mixed with water or juice, taken consistently.

NMN question: Ask whether the published trial-dose context from Igarashi 2022 is relevant to the person in front of the clinician. There is no evidence in sarcopenia that higher self-directed doses are useful.

Monitoring at week 12: Repeat grip strength using a hand dynamometer (most physiotherapy clinics have one), the 5-time chair-stand test (time how long it takes to stand up from a chair five times without using arms), and 4-metre walking speed. Compare to baseline.

If the foundation work has been consistent and the numbers have moved, attribute most of the gain to the training and protein, with a small possible contribution from NMN. If the numbers have not moved, the supplement is not the issue - review the consistency of the training and protein intake.

Drug interactions and the older Malaysian patient

Older Malaysian adults are commonly on multiple medications. The starting checklist for someone considering NMN should include a polypharmacy review.

Statins are particularly worth flagging - atorvastatin and simvastatin can cause statin-associated muscle symptoms in 5-10 percent of patients, and the symptoms (muscle aches, weakness, occasionally elevated CK) can confound any sarcopenia assessment. If you have started a statin recently and are now wondering about muscle weakness, talk to your prescriber about whether the statin or the underlying sarcopenia is driving the symptom.

NMN itself has no documented interaction with statins. Continuing the statin is generally appropriate; the cardiovascular event reduction evidence is robust. NMN does not alter statin pharmacokinetics or the risk of statin-induced myopathy.

Other commonly co-prescribed medications in older Malaysian adults - antihypertensives, metformin, vitamin D, omeprazole, allopurinol - have no documented interaction with NMN. Anticoagulants and antiplatelets carry a theoretical bleeding-time concern at high NAD+ states; some clinicians advise pausing supplements before a planned operation, so ask your doctor and surgeon how far in advance rather than relying on a fixed number.

A geriatric review is worth considering if you take five or more chronic medications. UM Medical Centre, IMU, Pantai and Sunway have geriatric services in Klang Valley; Penang and Kota Kinabalu also have access through major hospitals. Geriatricians can de-prescribe medications no longer needed and reduce the polypharmacy load before adding any supplement.

Halal context for elderly Muslim patients

The molecular concerns around halal compliance are the same as for any NMN product: the molecule itself is fermentation-derived and free of animal materials, but the capsule shell, excipients and manufacturing line need to be checked. For elderly Muslim patients, a few additional practical points are worth highlighting.

Capsule swallowing can be more difficult with age, and some halal-certified Malaysian brands now offer powder formulations or smaller capsule sizes that may be more practical. JAKIM-recognised certification is preferred. If a patient is on multiple supplements (vitamin D, calcium, omega-3, NMN), keeping the regimen simple - once-daily morning routine, fewer capsules - improves adherence.

For Muslim patients fasting during Ramadan, ask how supplement timing should be handled around sahur/iftar, and check with your local religious authority if fasting validity is part of your decision.

Practical home assessment for Malaysian families

Family caregivers can perform a useful informal sarcopenia assessment at home, even without specialised equipment. Three tests cover most of what AWGS 2019 measures:

Sit-to-stand test: Time how long it takes the older adult to stand up from a sitting position five times in a row, without using arms for support. A time longer than 12 seconds is a flag for low strength and a reasonable trigger for a clinical review.

Walking speed: Mark a 4-metre stretch on a flat surface. Time how long it takes to walk it at usual pace. Less than 4 seconds is normal; more than 5 seconds suggests reduced physical performance.

Calf circumference: Measure the largest part of the calf in centimetres while seated. Below 33cm in men or 32cm in women is a flag for possible low muscle mass - useful for community screening, though less precise than DXA.

These three measures take five minutes and can be repeated quarterly. They give a family a clear view of whether interventions are helping. They also give a Malaysian GP something concrete to discuss at the next visit.

Cost and budget priorities

For a Malaysian family considering supplements for an aging parent or grandparent, the order of spending should reflect the evidence:

1. Resistance training programme (free or low-cost via home equipment)
2. Adequate protein in the diet (food, not powder, where possible)
3. Vitamin D 800-2000 IU daily if levels are low (very common in Malaysian elderly despite year-round sunshine due to indoor lifestyles)
4. Creatine monohydrate 3-5g daily (around RM 30-60 per month)
5. NMN 250mg daily (around RM 120-280 per month)

If the budget for supplements is RM 100 per month, spend it on protein and creatine. If the budget allows RM 300 per month after those basics are covered, NMN can become a lower-priority discussion point. If the budget is constrained, do not skip the resistance training to afford the supplement; the supplement without the training does not produce the muscle.

Bottom line for an aging Malaysian

Sarcopenia is a real, addressable, and underdiagnosed condition in Malaysian older adults. The interventions with the strongest evidence are resistance training, protein adequacy, vitamin D where deficient, and creatine. NMN has a small published physical-performance signal from Igarashi 2022, with separate human safety support from Okabe 2022, but it belongs behind the foundation interventions and inside a clinician discussion.

The honest order of operations is unchanged. Train. Eat enough protein. Walk daily. Address polypharmacy. Add creatine if budget allows. Add NMN if budget still allows after that.

Monitor grip strength, gait speed and chair-stand performance every three months. Adjust based on what the numbers say, not what the marketing says.

That is the position the published evidence supports today, and it is the position that gives an aging Malaysian the best return on each ringgit spent.